Redesigning a large-scale clinical trial in response to negative external trial results: the CAMUS study of Phytotherapy for Benign Prostatic Hyperplasia

Abstract

Background Benign prostatic hyperplasia (BPH), a common condition among older men, confers its morbidity through potentially bothersome lower urinary tract symptoms. Treatments for BPH include drugs such as alpha-adrenergic receptor blockers and 5-alpha reductase inhibitors, minimally invasive therapies that use heat to damage or destroy prostate tissue, and surgery including transurethral resection of the prostate. Complementary and alternative medicines are gaining popularity in the US. Two phytotherapies commonly used for BPH are extracts of the fruit of Serenoa repens, the Saw palmetto dwarf palm that grows in the Southeastern US, and extracts of the bark of Pygeum africanum, the African plum tree.

Purpose The objective of the Complementary and Alternative Medicines for Urological Symptoms (CAMUS) clinical trial is to determine if phytotherapy is superior to placebo in the treatment of BPH.

Methods CAMUS was originally designed as a 3300-participant, four-arm trial of S. repens, P. africanum, an alpha-adrenergic blocking drug, and placebo with time to clinical progression of BPH, a measure of long-term efficacy, as the primary endpoint. Before enrollment started, a randomized, double-blind, placebo-controlled, single institution clinical trial showed that S. repens at the usual dose did not demonstrate any benefit over placebo with respect to symptom relief at 1 year. Consequently, the focus of CAMUS shifted from evaluating long-term efficacy to determining if any short-term (6—18 months) symptom relief could be achieved with increasing doses of S. repens, the phytotherapy most commonly used in the US for BPH.

Results Results are anticipated in 2011.

Conclusions Trial design occurs in an environment of continually evolving information. In this case, emerging results from another trial suggested that a study of long-term efficacy was premature, and that an effective dose and preparation of S. repens had to be established before proceeding to a long-term clinical trial. Clinical Trials 2009; 6: 628—636. http://ctj.sagepub.com

Get full access to this article

View all access options for this article.

References

Jacobsen SJ , Girman CJ , Guess HA , et al. New diagnostic and treatment guidelines for benign prostatic hyperplasia. Potential impact in the United States. Arch Intern Med 1995; 155: 477-81.

Litman HJ , McKinlay JB The future magnitude of urological symptoms in the USA: projections using the Boston Area Community Health survey. BJU Int 2007; 100: 820-5.

AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia. Chapter 1. Diagnosis and treatment recommendations. J Urol 2003 ; 170: 530-47.

Roehrborn CG , Nuckholls JG , Wei JT , Steers W. The benign prostatic hyperplasia registry and patient survey: study design, methods and patient baseline characteristics . BJU Int 2007; 100: 813-9.

McConnell JD , Brusketwitz R. , Walsh P. , et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349: 2387-98.

Bautista OM , Kusek JW , Nyberg LM , et al. Study design of the Medical Therapy of Prostatic Symptoms (MTOPS) trial. Control Clin Trials 2003; 24: 224-43.

Gardiner P. , Graham R. , Legedza AT , et al. Factors associated with herbal therapy use by adults in the United States. Altern Ther Health Med 2007 ; 13: 22-9.

Fourcade RO , Theret N. , Taieb C.

Profile and management of patients treated for the first time for lower urinary tract symptoms/benign prostatic hyperplasia in four

European countries. BJU Int 2008; 101: 1111-8.

Dedhia RC , McVary KT Phytotherapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2008; 179: 2119-25.

10.

Gerber GS Saw palmetto for the treatment of men with lower urinary tract symptoms. J Urol 2000; 163: 1408-12.

11.

Ishani A. , MacDonald R. , Nelson D. , et al. Pygeum africanum for the treatment of patients with benign prostatic hyperplasia: a systematic review and quantitative meta-analysis. Am J Med 2000; 109: 654-64.

12.

Tacklind J. , MacDonald R. , Turks I. , Wilt TJ Serenoa repens for benign prostatic hyperplasia . Cochrane Database Syst Rev 2009: CD001423.

13.

Wilt T. , Ishani A. , Mac Donald R. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev 2002: CD001423.

14.

Wilt T. , Ishani A. , MacDonald R. , et al. Pygeum africanum for benign prostatic hyperplasia. Cochrane Database Syst Rev 2002: CD001044.

15.

Thompson IM , Goodman PJ , Tangen CM , et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349: 215-24.

16.

Bent S. , Kane C. , Shinohara K. , Neuhaus J. , et al. Saw palmetto for benign prostatic hyperplasia. N Engl J Med 2006; 354: 557-66.

17.

Hypericum Depression Trial Study Group. Effect of Hypericum perforatum (St John’s wort) in major depressive disorder: a randomized controlled trial. JAMA 2002; 287: 1807-14.

18.

Turner RB , Bauer R. , Woelkart K. , et al. An evaluation of Echinacea angustifolia in experimental rhinovirus infections. N Engl J Med 2005; 353: 341-8.

19.

Sampson W. Studying herbal remedies. N Engl J Med 2005 ; 353: 337-9.

20.

DiPaola RS , Morton RA Proven and unproven therapy for benign prostatic hyperplasia. N Engl J Med 2006; 354: 632-4.

21.

Habib FK , Wyllie MG Not all brands are created equal: a comparison of selected components of different brands of Serenoa repens extract. Prostate Cancer Prostatic Dis 2004; 7: 195-200.

22.

Clark RV , Hermann DJ , Cunningham GR , et al. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5-alpha-reductase inhibitor. J Clin Endocrinol Metab 2004; 89: 2179-84.

23.

Breitner JC , Martin BK , Meinert CL The suspension of treatments in ADAPT: concerns beyond the cardiovascular safety of celecoxib or naproxen. PLoS Clin Trials 2006; 1: e41.

24.

Nissen SE ADAPT: the wrong way to stop a clinical trial. PLoS Clin Trials 2006; 1: e35.